Is there a way to lessen the devastating lung damage that often follows radiation therapy for thoracic cancers? A new study suggests that hyperthermia, a treatment involving the application of heat, could be a game-changer in protecting patients from this debilitating side effect. Published in BMC Cancer on November 8, 2025, this open-access research dives deep into the potential benefits of combining hyperthermia with radiotherapy. Here’s what you need to know.
This retrospective study, spearheaded by Wentao Gao, Jiafeng Liang, Lucheng Zhu and their team, explores the impact of adding hyperthermia to standard radiotherapy for patients battling thoracic malignancies. The core question? Can hyperthermia reduce the incidence of radiation pneumonitis (RP), a common and serious complication of thoracic radiotherapy?
The Study in a Nutshell
The researchers meticulously analyzed data from 233 patients with thoracic malignancies admitted between 2017 and 2020. These patients were divided into two groups: one receiving radiotherapy alone (RT group, N = 119) and the other receiving radiotherapy combined with hyperthermia (RHT group, N = 114). The study followed patients for three months before radiotherapy and six months post-treatment, carefully tracking and comparing the incidence of RP in both groups. This follow-up period is critical as RP typically develops within six months of starting radiotherapy.
Key Findings: A Ray of Hope?
The results revealed a compelling trend. Among patients whose lungs received a radiation dose exceeding 20 Gy (V20 > 20%), the incidence of grade ≥ 2 RP was significantly lower in the RHT group (33.33%) compared to the RT group (55.32%). This difference was statistically significant (P = 0.034), suggesting a protective effect of hyperthermia. Furthermore, the study found a significant correlation between the number of hyperthermia sessions and the incidence of RP (P = 0.043), indicating that more frequent hyperthermia treatments might lead to better outcomes. Multivariate analysis further solidified these findings, identifying gender, performance status (PS) score, and the number of hyperthermia sessions as independent factors associated with the incidence of grade ≥ 2 RP.
In simpler terms: For patients receiving higher doses of radiation to their lungs, adding hyperthermia to their treatment plan appeared to significantly reduce the risk of developing moderate to severe radiation pneumonitis.
Why This Matters: The Bigger Picture
Radiation therapy is a cornerstone in treating thoracic cancers, particularly lung and esophageal tumors. Comprehensive chemoradiation has become a standard of care, significantly improving survival rates. However, this powerful treatment comes with a significant drawback: radiation pneumonitis. Even with advancements in precision radiotherapy, the incidence of RP remains stubbornly high, with studies reporting grade ≥ 2 RP in up to 30% of patients and severe grade 3 or higher RP in as many as 18%. And this is the part most people miss: as more patients receive targeted therapies and immunotherapies (extending their survival), many will still require thoracic radiotherapy for disease progression, making the prevention and management of RP even more critical.
RP can derail treatment plans, severely impacting a patient's survival and prognosis. Current treatments for RP primarily involve corticosteroids, which, while effective, can interfere with the efficacy of subsequent immunotherapies. Moreover, existing clinical practices struggle to accurately predict RP occurrence, making preventative strategies all the more crucial. This is where hyperthermia steps in, offering a potential solution to mitigate this devastating side effect.
Hyperthermia: A Promising Partner for Radiotherapy
Hyperthermia involves applying heat to target tumor regions, enhancing the effectiveness of conventional treatments like radiotherapy, chemotherapy, and targeted immunotherapy. It's particularly useful for tumors that are resistant to these treatments, improving therapeutic efficacy and local control rates. Hyperthermia has already been integrated into radiotherapy for various thoracic malignancies, showing promising results. For example, a case report highlighted how hyperthermia, combined with chemoradiotherapy, converted inoperable esophageal cancer into a resectable condition. Another case demonstrated the benefit of combined hyperthermia and radiotherapy in a patient with non-small-cell lung cancer who couldn't tolerate standard chemoradiotherapy.
The Controversy & Comment Hooks
While the study suggests a significant benefit, it's important to note that the study had some limitations. As a retrospective study, the baseline data balance of the patients in this study was not optimal. Furthermore, due to the relatively small sample size for some analyses, there may be some error regarding the impact of the number of hyperthermia times on the occurrence of RP. But here's where it gets controversial... The authors themselves acknowledge that further research with larger, more standardized studies is needed to confirm these findings. Also, the study found that although the incidence of grade ≥ 2 RP was lower in the RHT group, the incidence of grade < 2 RP appeared to be higher. What are your thoughts on this? Could this indicate a shift towards milder, more manageable forms of RP, or does it raise concerns about other potential side effects of hyperthermia?
Delving Deeper: How Does Hyperthermia Protect the Lungs?
The study suggests that hyperthermia might improve patient tolerance and reduce lung damage by inducing heat shock proteins (HSPs) and improving local blood flow. HSPs, such as HSP27, HSP70, and HSP90, are produced in response to heat stress and have been shown to protect against radiation-induced lung injury. HSP70, in particular, may play a role in DNA repair and possess cytoprotective properties. Additionally, hyperthermia-induced vasodilation and increased blood flow may help clear inflammatory mediators, preventing the development of a cytokine storm and reducing the risk of RP. However, it's essential to remember that HSP70 may also inhibit apoptosis, potentially compromising treatment efficacy. Moreover, their effect is also transient, with expression peaking within hours and declining thereafter. This is why, in clinical practice, hyperthermia times are typically scheduled one to three times per week to sustain their biological influence. Thus, while HSPs induction likely contributes to the observed reduction in RP, it should be interpreted as a partial mechanism rather than the sole explanatory factor.
The Methods: A Closer Look
The study included patients with thoracic tumors (esophageal cancer, lung cancer, thymoma) who received thoracic radiotherapy with a dose of ≥ 30 Gy. Patients also had to have CT imaging within three months before radiotherapy, during radiotherapy, within one month after radiotherapy, and between three to six months after radiotherapy. Exclusion criteria included patients who received stereotactic body radiotherapy for metastatic lesions, underwent radiotherapy to the tumor bed after surgery, had pre-existing pneumonitis, or received re-irradiation for thoracic lesions. The radiotherapy was delivered using advanced techniques like intensity-modulated radiotherapy (IMRT) and volume-modulated arc therapy (VMAT). Hyperthermia was administered using a high-frequency system, with the target volume temperature maintained between 41–43 ℃ for 45–60 minutes, twice weekly, beginning on the first day of radiotherapy.
Conclusions: A Step Forward, But More Research Needed
The study concludes that, in patients with V20 > 20%, hyperthermia can significantly reduce the incidence of RP, especially grade ≥ 2 RP, and that increasing the number of hyperthermia sessions further reduces the risk. The authors also identified gender, PS score, and the number of hyperthermia sessions as factors influencing RP occurrence after thoracic radiotherapy.
What do you think about these findings? Could hyperthermia become a standard addition to thoracic radiotherapy? Do you believe the potential benefits outweigh the costs and logistical challenges of implementing hyperthermia in clinical practice? Share your thoughts and experiences in the comments below!
